Latest news

• bluebird bio to separate oncology and rare diseases units

  Oncology Newco will assume responsibility for a number of bluebird bio’s current oncology assets, including its investigational BCMA-targeting CAR T therapy idecabtagene vicleucel (ide-cel), which is currently being ... In addition, Oncology Newco will

• Bluebird bio leans on pipeline and Zynteglo launch as revenues fall

  Bluebird is in partnership with BMS for a BCMA-targeting cell therapy – bb2121 or ide-cel – which recently demonstrated positive top-line results in multiple myeloma. ... Aside from the mixed figures, bluebird is looking forward and focusing on the

• FDA begins speedy review of BMS’ CAR-T liso-cel

  or whose disease has relapsed,” said Stanley Frankel, senior vice president, cellular therapy development, BMS. ... In addition to liso-cel, BMS has another CAR-T therapy in the pipeline – its bluebird bio-partnered BCMA-targeting therapy bb2121 for

• J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data

  Both candidates are being studied in multiple myeloma. Johnson and Johnson and Bristol-Myers Squibb/Bluebird bio have both revealed data from their respective BCMA-targeting CAR-T therapies in multiple ... BMS/Bluebird also had their own CAR-T data in

• GSK preps filings for BCMA-targeting multiple myeloma drug

  GSK2857916 is one of a slew of BCMA-targeting therapies coming through the biopharma industry pipeline, jostling for position with a CAR-T therapy from Celgene and Bluebird Bio called bb2121 ... It is the most advanced BCMA-targeting ADC in development,